Genflow Biosciences Partners with Heureka Labs to Accelerate SIRT6 Gene Therapy Development Using AI
Key Insights
Genflow Biosciences (search) has formed a strategic partnership with Duke University spin-off Heureka Labs (search) to leverage AI technology for analyzing complex genomic data in gene therapy research.
The collaboration will initially support Genflow's lead candidate GF-1002, a centenarian SIRT6 (search)-based gene therapy in preclinical evaluation, with potential expansion to other programs including treatments for MASH (search).
Under the Master Services Agreement signed on April 11, 2025, Genflow will retain all intellectual property rights while gaining access to advanced AI tools that promise to enhance therapeutic design and predict patient-specific outcomes.
Genflow Biosciences (search), Europe's only publicly listed longevity company, announced on April 14, 2025, that it has entered into a strategic partnership with Heureka Labs (search), a U.S.-based artificial intelligence platform specializing in genomic data analysis. The collaboration aims to accelerate the development of gene therapies targeting age-related diseases and longevity.
The partnership was formalized through a Master Services Agreement (MSA) signed on April 11, 2025, establishing a framework for long-term collaboration between the two companies. Under the agreement, Genflow will retain all intellectual property rights while gaining access to Heureka's sophisticated AI tools.
AI-Powered Genomic Analysis
Heureka Labs (search), a technology spin-off from Duke University, will provide Genflow with access to its proprietary AI platform, which specializes in analyzing high-dimensional genomic data, including RNA sequencing and gene expression profiles. This technology is expected to significantly enhance Genflow's ability to interpret complex biological datasets.
"Incorporating AI is no longer optional in bioinformatics research—it's essential for precision, speed, and scale," said Dr. Eric Leire, CEO of Genflow. "Heureka's AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on."
The AI platform is designed to generate testable hypotheses, uncover unexpected biological patterns, and improve research and development efficiency. These capabilities will enable deeper insights into gene regulatory networks and systemic biological responses, which are critical for optimizing therapeutic design and anticipating patient-specific outcomes.
Advancing SIRT6 Gene Therapy
Initial efforts under the partnership will support Genflow's lead candidate, GF-1002, a gene therapy based on a centenarian variant of the SIRT6 (search) gene. The therapy is currently in preclinical evaluation, with a 12-month proof-of-concept clinical trial in aged dogs having begun in March 2025.
The SIRT6 (search) gene has garnered significant attention in longevity research due to its role in DNA repair, genomic stability, and metabolic regulation. The centenarian variant being utilized by Genflow has shown promising results in preclinical studies for potentially extending healthy lifespan.
Expanding Therapeutic Applications
Beyond its primary focus on longevity, Genflow plans to extend the application of its gene therapy approach to specific age-related conditions. The partnership with Heureka Labs (search) may support future pipeline programs, including those targeting Metabolic Dysfunction-Associated Steatohepatitis (search) (MASH (search)), the most prevalent chronic liver disease for which there are currently no effective treatments.
Additionally, Genflow recently announced a new development program in ophthalmology, suggesting a broadening therapeutic focus for its gene therapy platform. Age-related eye conditions represent a significant unmet medical need, with millions of older adults affected by conditions such as macular degeneration and glaucoma.
Market and Industry Context
The collaboration comes at a time when the longevity sector is gaining increased attention from investors and pharmaceutical companies. With an aging global population, the economic and healthcare burdens associated with age-related diseases continue to grow, creating urgent demand for interventions that can extend healthy lifespan.
Dr. Leire emphasized this point, noting that their work aims at "accelerating the delivery of safe and effective therapies that promote a healthier lifespan, while helping to ease the growing operational and economic burden of an aging population."
AI in Drug Discovery
Heureka's AI platform is already in use by leading pharmaceutical and biotechnology companies, reflecting the growing industry trend toward AI-augmented drug discovery and development. AI technologies have demonstrated the potential to significantly reduce the time and cost associated with bringing new therapies to market.
For gene therapy specifically, AI can help identify optimal delivery vectors, predict off-target effects, and personalize treatment approaches based on individual genetic profiles. These capabilities align well with Genflow's focus on developing targeted gene therapies for age-related conditions.
The partnership between Genflow Biosciences (search) and Heureka Labs (search) represents a convergence of two cutting-edge fields—gene therapy and artificial intelligence—in pursuit of novel approaches to extending healthy human lifespan. As the collaboration progresses, it may yield valuable insights not only for Genflow's specific therapeutic candidates but also for the broader field of longevity research.